OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
🏛 Food and Drug Administration (HHS-FDA)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for health equity research and innovation led by the FDA's Office of Minority Health and Health Equity. Eligible applicants include 501(c)(3) nonprofits, research institutions, academic medical centers, and health organizations. Domestic institutions in all U.S. states and territories can apply. The grant supports projects that advance health equity in FDA-regulated products and services, excluding clinical trials and direct patient care delivery.
Not the right fit? Find grants for your organization in 5 questions →
Program description
The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance minority health and health equity objectives.
Areas of interest include:
Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Required documents
- SF-424 (R&R) Federal Grant Application Cover Sheet
- Project Narrative (with specific aims and innovation approach)
- Budget and Budget Justification
- Biographical Sketches of Key Personnel
- Letters of Support from Partners/Community
- Institutional Commitment Documentation
- Data Management Plan (if applicable)
Program contact
- 👤 Terrin Brown Grantor
- 📧 terrin.brown@fda.hhs.gov
- 📞 2404027610
Funding track record
Recent awards under CFDA 93.103 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$121,795,918
-
$76,105,626
-
$50,217,964
-
$47,940,304
-
$36,000,000
-
$35,573,997
-
$35,391,995
-
$30,732,300
-
$23,332,999
-
$21,347,288
Top States by Funding
- AZ 3 awards $131.4M
- MD 7 awards $108.7M
- CA 9 awards $106.5M
- VA 5 awards $96.6M
- PA 10 awards $77.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.103). How funding has trended year over year.
| 2016 | $170,482,435 | |
| 2017 est. | $208,900,832 | |
| 2018 | $173,077,408 | |
| 2019 | $198,507,896 | |
| 2020 | $212,448,590 | |
| 2021 | $218,918,739 | |
| 2022 est. | $255,910,458 | |
| 2023 est. | $246,894,600 |
FAQ
What types of organizations can apply?
501(c)(3) nonprofits, universities, research institutions, medical centers, and health organizations are eligible. Institutions must be domestic and able to manage federal funds.
Are clinical trials allowed?
No. This funding explicitly excludes clinical trials. Research must focus on equity innovation and systems improvement, not human subjects testing.
What activities does this grant support?
Projects addressing health equity in FDA-regulated areas like medications, devices, diagnostics, and food safety. Eligible work includes research, implementation, workforce development, and capacity building.
How competitive is this grant?
Very competitive. This is a federal R&D program. Strong applications require preliminary data, clear equity focus, and institutional commitment to health equity.
What is the typical funding range?
U01 awards typically support multi-year projects with budgets ranging from $250,000 to $500,000 annually, though amounts vary by project scope and innovation approach.
💡 Tips for applicants
- Center your project on a specific health equity gap in FDA-regulated products or services. Generic equity statements will not be competitive.
- Include letters of support from community partners and patient advocates affected by the equity issue you're addressing.
- Highlight preliminary data demonstrating the problem and feasibility of your proposed solution.
- Clearly explain how your innovation will achieve sustainable, scalable impact beyond the funding period.
- Align your project with FDA priorities and ongoing health equity initiatives within the agency.
⚠️ Common mistakes
Applicants fail to clearly define health equity problems specific to FDA-regulated products. Including clinical trial components or direct patient care delivery disqualifies applications. Weak institutional commitment or lack of community partnership diminishes competitiveness.
Similar grants
- ROLLING Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed — Food and Drug Administration
- ROLLING OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed — Food and Drug Administration
- CLOSED FDA OMHHE Convener for Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH) — Food and Drug Administration
- ROLLING Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed — Food and Drug Administration
- ROLLING REACHing Communities (REACH) Consortium (U01) Clinical Trials Optional — Food and Drug Administration